Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Nov 20, 2022
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") will present the efficacy, safety and biomarker findings from the company's Phase 3 confirmatory Clarity AD clinical trial for...
-
Oct 21, 2022
Data Include Provider-Reported Best Overall Response (BOR), Progression-Free Survival and Overall Survival in U.S. Patients NUTLEY, N.J., Oct. 21, 2022 /PRNewswire/ -- Eisai today announced final...
-
Sep 27, 2022
ALL KEY SECONDARY ENDPOINTS ALSO MET, DEMONSTRATING HIGHLY STATISTICALLY SIGNIFICANT RESULTS PROFILE OF AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA) INCIDENCE WAS WITHIN EXPECTATIONS EISAI AIMS TO...
-
Sep 10, 2022Findings to be featured in a late-breaking proffered paper session at European Society for Medical Oncology (ESMO) Congress 2022
RAHWAY, N.J. and NUTLEY, N.J., Sept. 10, 2022 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced the first presentation of results from the...
-
Sep 10, 2022
Analysis Evaluates Efficacy of Eribulin in Metastatic HER2-low Breast Cancer Across Three Studies (Presentation: #259P) NUTLEY, N.J., Sept. 10, 2022 /PRNewswire/ -- Eisai announced today results...